Get the Stockscreener App
53.94
3.68%
-2.06
After Hours:
52.92
-1.02
-1.89%
Exact Sciences Corp stock is traded at $53.94, with a volume of 2.27M.
It is down -3.68% in the last 24 hours and up +29.23% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$56.00
Open:
$56.22
24h Volume:
2.27M
Relative Volume:
0.73
Market Cap:
$10.21B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-9.7895
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
+0.24%
1M Performance:
+29.23%
6M Performance:
+16.38%
1Y Performance:
-19.96%
1-Day Range:
$53.88
$56.33
1-Week Range:
$52.16
$56.52
52-Week Range:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
53.94 | 10.37B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Curi RMB Capital LLC Sells 10,902 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Graham Capital Management L.P. Buys New Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs - Nasdaq
Exact Sciences price target raised to $85 from $65 at Craig-Hallum - Yahoo Finance
Exact Sciences Corporation $EXAS Shares Sold by Vident Advisory LLC - MarketBeat
Exact Sciences (NASDAQ:EXAS) Cut to Hold at Zacks Research - MarketBeat
Exact Sciences (EXAS) Is Up 11.2% After Launching Cancerguard Multi-Cancer Blood Test With Quest Diagnostics - simplywall.st
Exact Sciences launches blood test that can detect cancers earlier - Wisconsin State Journal
EFG Asset Management North America Corp. Decreases Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS Stock Position Decreased by Northwestern Mutual Wealth Management Co. - MarketBeat
Exact Sciences Launches Cancerguard™, Multi-Cancer Early Detection Blood Test - Nasdaq
Exact Sciences Corporation (NASDAQ:EXAS) Short Interest Update - MarketBeat
Exact Sciences’ Cancerguard MCED test launches for $689 - BioWorld MedTech
Exact Sciences launches Cancerguard blood test for early cancer detection By Investing.com - Investing.com Nigeria
Should You Continue to Hold EXAS Stock in Your Portfolio? - Nasdaq
Scientech Research LLC Buys Shares of 21,144 Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences launches Cancerguard blood test for early cancer detection - Investing.com
Exact Sciences launches Cancerguard multi-cancer blood test at $689 - StreetInsider
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test - Morningstar
Granahan Investment Management LLC Decreases Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Edmond DE Rothschild Holding S.A. Boosts Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Wisconsin InnoExact Sciences' multi-cancer blood test | Curate acquired - The Business Journals
Exact Sciences at Baird Conference: Strategic Growth in Cancer Screening - Investing.com
Transcript : Exact Sciences Corporation Presents at Baird Global Healthcare Conference 2025, Sep-09-2025 10 - MarketScreener
Raymond James Financial Inc. Lowers Stake in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences And 2 Other Stocks Estimated To Be Trading Below Their Fair Value - Yahoo Finance
Baird Financial Group Inc. Sells 25,414 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Aug Ideas: Can Exact Sciences Corporation sustain its profitabilityJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - 뉴스영
Ieq Capital LLC Increases Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Should you wait for a breakout in Exact Sciences CorporationJuly 2025 Summary & Daily Technical Stock Forecast Reports - Newser
Exact Sciences Corporation $EXAS Shares Sold by Lansforsakringar Fondforvaltning AB publ - MarketBeat
Can Exact Sciences Corporation be the next market leaderPortfolio Update Report & Expert Verified Movement Alerts - خودرو بانک
Exact Sciences, Humana Expand Colorectal Cancer Screening Collaboration - Medical Product Outsourcing
What hedge funds are buying Exact Sciences Corporation2025 Bull vs Bear & Daily Stock Momentum Reports - خودرو بانک
Is Exact Sciences Corporation stock entering bullish territoryQuarterly Earnings Report & Risk Controlled Daily Plans - Newser
What momentum shifts mean for Exact Sciences CorporationMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
Exact Sciences Surges Into Top 300 Most Traded Amid Mixed Analyst Outlooks and Volatile Investor Sentiment - AInvest
Exact Sciences Corporation shares rise 6.23% intraday after Senzime AB's TetraGraph® selected by California hospital system. - AInvest
Why Exact Sciences (EXAS) Stock Is Trading Up Today - Yahoo Finance
How to build a custom watchlist for Exact Sciences CorporationNew Guidance & Safe Entry Point Identification - Newser
Will Exact Sciences Corporation stock go up soonJuly 2025 Final Week & Reliable Momentum Entry Alerts - Newser
Exact Sciences at Wells Fargo Conference: Strategic Growth Insights - Investing.com
Exact Sciences (EXAS) Stock Trades Up, Here Is Why - Yahoo Finance
Analyzing drawdowns of Exact Sciences Corporation with statistical toolsWeekly Stock Analysis & Community Consensus Picks - Newser
Applying Wyckoff theory to Exact Sciences Corporation stockRecession Risk & Weekly High Return Forecasts - Newser
Real time scanner hits for Exact Sciences Corporation explained2025 Fundamental Recap & Expert Curated Trade Setup Alerts - Newser
Exact Sciences Corporation $EXAS Shares Acquired by Rafferty Asset Management LLC - MarketBeat
How to escape a deep drawdown in Exact Sciences CorporationForecast Cut & AI Driven Stock Movement Reports - Newser
Exact Sciences Corporation $EXAS Shares Sold by Northern Trust Corp - MarketBeat
Volume spikes in Exact Sciences Corporation stock – what they meanRate Cut & Low Risk Growth Stock Ideas - Newser
Evaluating Exact Sciences Corporation with trendline analysisJuly 2025 Price Swings & Community Trade Idea Sharing Platform - Newser
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):